Masimo Corporation Stock Intrinsic Value – MASIMO CORPORATION Reports FY2023 Q2 Earnings Results for June 30 2023

August 28, 2023

🌥️Earnings Overview

On August 8th, 2023, Masimo Corporation ($NASDAQ:MASI) reported their Q2 FY2023 earnings results as of June 30th, 2023. Total revenue for the second quarter was USD 455.3 million, which was a 19.5% decrease year-over-year from the same period in the previous year. Net income also decreased 13.3% to USD 15.7 million compared to the same period in FY2022.

Share Price

On Tuesday, MASIMO CORPORATION reported their financial results for the second quarter of their fiscal year 2023, ending on June 30, 2023. The company’s stock opened at $122.1 and closed at $120.0, representing a 2.4% decrease from its prior closing price of $123.0. This improvement was driven by an increase in cash from operations, which was partially offset by an increase in capital expenditures and debt principal payments.

Overall, MASIMO CORPORATION reported a solid set of financial results for its fiscal year 2023 second quarter, with strong revenue growth and improved cash position driving the company’s performance. The company continues to focus on expanding its product portfolio in order to drive future growth. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Masimo Corporation. More…

    Total Revenues Net Income Net Margin
    2.19k 115.8 5.1%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Masimo Corporation. More…

    Operations Investing Financing
    27.8 -64 -15.5
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Masimo Corporation. More…

    Total Assets Total Liabilities Book Value Per Share
    3.01k 1.7k 24.77
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Masimo Corporation are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    27.8% -7.1% 9.3%
    FCF Margin ROE ROA
    -1.3% 9.6% 4.2%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Masimo Corporation Stock Intrinsic Value

    At GoodWhale, we have conducted an analysis of MASIMO CORPORATION’s financials. Our proprietary Valuation Line has concluded that the fair value of the share of MASIMO CORPORATION is around $325.9. Taking into consideration the current market price, we observe that MASIMO CORPORATION’s stock is currently being traded at $120.0, undervalued by 63.2%. This presents a great buying opportunity for investors who are looking to make a long-term investment in the company. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    In the medical device industry, there is intense competition between Masimo Corp and its rivals Elekta AB, Essilorluxottica, and Compumedics Ltd. While all four companies offer innovative products and services, each has its own unique strengths and weaknesses. As a result, the competition between them is fierce, and it is often difficult for one company to gain a significant advantage over the others.

    – Elekta AB ($OTCPK:EKTAY)

    Despite a challenging year for the company, Elekta’s market cap has grown to 2.09B as of 2022. This is due in part to the company’s strong return on equity, which stands at 11.86%. Elekta is a leading provider of radiation therapy solutions for the treatment of cancer. The company’s products are used in over 6,000 hospitals and clinics around the world, and its solutions are backed by a team of over 3,000 employees.

    – Essilorluxottica ($LTS:0OMK)

    EssilorLuxottica is a French-Italian multinational corporation that designs, manufactures, and markets ophthalmic lenses, instruments, and equipment. The company has a presence in over 130 countries and employs more than 140,000 people. The company was formed in 2018 through the merger of Essilor International and Luxottica.

    – Compumedics Ltd ($ASX:CMP)

    Computedics Ltd is a technology company that provides computing and analytics solutions. The company has a market cap of 42.52M as of 2022 and a Return on Equity of 1.53%. Computedics Ltd provides computing and analytics solutions to businesses and organizations worldwide. The company offers a range of services, including data storage, cloud computing, data analysis, and security. Computedics Ltd is headquartered in Sydney, Australia.


    Investors should take note of the recent earnings report from Masimo Corporation for the second quarter of 2023. Total revenue was USD455.3 million, a decrease of 19.5% year-over-year. Net income also decreased 13.3% to USD15.7 million.

    Short-term investors may be discouraged by the company’s declining revenue and income, however long-term investors should consider Masimo’s continued commitment to research and development, as well as their potential to capitalize on emerging technologies. Masimo is also in a competitive position due to their partnerships with multiple healthcare providers, and their ability to provide a range of innovative medical devices and therapies.

    Recent Posts

    Leave a Comment